Ifosfamide-Induced Encephalopathy Successfully Prevented by Methylene Blue: A Pediatric Case Report and Review of the Literature (2023)

Peer-Reviewed Study · Furui K; Komori K; Kurata K; Sakashita K · June 10, 2023

Furui K et al., 2023-06-10: Paediatric case report of a three-year-old girl with Ewing's sarcoma who developed ifosfamide-induced encephalopathy and was then given methylene blue prophylactically, allowing ifosfamide to be completed without recurrence. The authors call for clinical trials to confirm efficacy and safety in children.

we report the case of a three-year-old girl who developed IIE during chemotherapy for Ewing's sarcoma and was treated with methylene blue as a prophylactic agent for IIE, after which she continued with ifosfamide and completed treatment without IIE recurrence.

Furui K et al., 2023-06-10: Paediatric case report of a three-year-old girl with Ewing's sarcoma who developed ifosfamide-induced encephalopathy and was then given methylene blue prophylactically, allowing ifosfamide to be completed without recurrence. The authors call for clinical trials to confirm efficacy and safety in children. Study type: single case report with literature review. N=1 patient. Country: Japan. Dose/route: methylene blue prophylactic dosing per full text (IV). Comparator: none. Prior/concurrent treatment: ifosfamide chemotherapy for Ewing's sarcoma. Funder/conflicts: per full text. The authors explicitly note that further studies including clinical trials are needed, so this is uncontrolled evidence in a single child. Also filed as MTI-65 (claims C4, C6). Study type: case report.